
The number of patients aged 80 years and above presenting with cancer is rising rapidly. This group is characterized by physiological vulnerability, multimorbidity, polypharmacy, and diminished functional reserve, yet has been systematically excluded from the trials that define standard care. Comprehensive geriatric assessment (CGA) is a multidimensional evaluation of functional status, comorbidity, cognition, psychological state, social support, nutrition, and medication use, and has been proposed as the means of individualizing treatment where chronological age is an unreliable guide. This narrative review is centered on the assessment itself: what CGA measures, what randomized and observational evidence shows it achieves, how it can be delivered across differing resource settings including India, and where its supporting evidence is weakest. Randomized trials – principally GAP70+, GAIN and INTEGERATE – show that assessment with management reduces grade 3–5 treatment toxicity and improves patient-reported outcomes; a survival benefit has not been demonstrated, and no such trial has been restricted to patients aged 80 and above. Structured assessment outperforms unaided clinical judgment in identifying frailty. Evidence specific to the extremely elderly remains dominated by retrospective, single-center cohorts with selection bias toward fitter patients and inconsistent age thresholds; treatment-modality data are therefore summarized only insofar as CGA alters the decision, and are appraised explicitly for quality. Indian data derive almost entirely from a single tertiary center, where a majority of surveyed physicians report relying on clinical intuition rather than validated tools. For most Indian units, the practical starting point is routine screening with a validated instrument and focused assessment of domains for which local intervention exists, rather than a multidisciplinary clinic. Priorities for the field are prospective cohorts confined to the 80-plus group, recalibration of toxicity-prediction tools in Indian populations, and consensus on defining and reporting this age group.
Evidence generation is a multistep process that remains labor-intensive and time-consuming. Although artificial intelligence (AI)-enabled platforms support literature reviews, their complete automation is scarce. We utilized an online AI suite, SymproAI, to perform a fully automated targeted literature review (TLR) on treatment outcomes in patients with aquaporin-4 (AQP4)-positive neuromyelitis optica spectrum disorder (NMOSD) and compared its performance with the manual process. This TLR summarizes the efficacy and safety of Food and Drug Administration-approved biologics or conventional immunosuppressants in patients with AQP4-positive NMOSD using SymproAI. Performance was validated using sensitivity, specificity, predictive values, overall accuracy, and overall speed of performance. SymproAI searches demonstrated 98.2% agreement with the manual retrieval (1,721 vs. 1,691 citations). For title/abstract and full-text screening, SymproAI achieved 94.4% and 80.5% accuracy, respectively. SymproAI generated TLR-identified 44 publications identical to those provided by the manual review. Overall, the TLR timeframe was estimated at ~120 min using SymproAI, compared with 96 work hours required for the manual process. The generative feature of SymproAI demonstrated good agreement with human findings and data interpretation. Both processes agreed on eculizumab with the strongest relapse-prevention efficacy (94.2% risk reduction), followed by satralizumab (74–79%) and inebilizumab (73%). Across conventional therapies, rituximab demonstrated superior relapse prevention compared with these oral immunosuppressants (mycophenolate mofetil and azathioprine), reducing relative relapse risk by ~60% ( p = 0.046), highlighting its greater efficacy. SymproAI enables rapid, accurate, and reproducible automation of TLRs without compromising study selection or clinical conclusions, supporting accelerated and methodologically rigorous evidence synthesis in time-sensitive clinical settings.
Objectives: Pulmonary aspiration of gastric contents remains a recognized perioperative complication that can result in significant morbidity during general anesthesia. Pharmacological strategies aimed at increasing gastric pH and reducing residual gastric volume are commonly employed to decrease aspiration risk. This study evaluated the effectiveness of two pre-operative doses of omeprazole alone or in combination with domperidone on gastric pH, gastric volume, and duodenogastric reflux in patients undergoing elective surgery. Materials and Methods: In this prospective, randomized, placebo-controlled clinical trial, 180 adult patients (American Society of Anesthesiologists physical status I–II), aged 15–70 years and scheduled for elective surgery under general anesthesia, were enrolled. Participants were allocated equally into three groups ( n = 60 each). Group OD received omeprazole 40 mg plus domperidone 10 mg, Group O received omeprazole 40 mg alone, and Group C received placebo. Study medications were administered orally at 9:00 p.m. on the evening before surgery and again at 6:00 a.m. on the day of surgery. Following induction of anesthesia and endotracheal intubation, gastric contents were aspirated through an orogastric tube. Gastric fluid volume and pH were measured, and the presence of bile was assessed using Hay’s sulfur test. Results: Baseline demographic characteristics and perioperative timing variables were similar among the three groups. Patients receiving omeprazole plus domperidone demonstrated the most favorable gastric profile, with a mean gastric pH of 4.12 ± 0.50, gastric volume of 15.31 ± 4.03 mL, and positive bile reflux in 2 patients (3.77%). In comparison, patients receiving omeprazole alone had a gastric pH of 4.01 ± 0.67, gastric volume of 16.30 ± 4.78 mL, and positive bile reflux in 17 patients (28.33%). The placebo group showed a significantly lower gastric pH (2.02 ± 0.50), higher gastric volume (20.85 ± 10.50 mL), and positive bile reflux in 21 patients (35.00%). The combination regimen significantly reduced the proportion of patients meeting aspiration-risk criteria and decreased the occurrence of duodenogastric reflux compared with both omeprazole alone and placebo ( p < 0.0001). Conclusion: Administration of two consecutive pre-operative doses of omeprazole 40 mg combined with domperidone 10 mg was more effective than omeprazole alone or placebo in increasing gastric pH, reducing residual gastric volume, limiting duodenogastric reflux, and decreasing the number of patients classified as being at risk for aspiration. These findings support the use of combined acid-suppressive and prokinetic therapy as part of pre-operative aspiration prophylaxis in elective surgical patients.
Objectives: Mechanically ventilated preterm infants are at an increased risk of mortality due to complications related to prematurity and critical illness. Azithromycin has been studied as a potential adjunctive therapy due to its anti-inflammatory, immunomodulatory, and antimicrobial properties, particularly against Ureaplasma species. However, its effect on mortality in ventilated preterm infants remains unclear. The objective is to evaluate the effect of azithromycin on mortality in mechanically ventilated preterm infants. Materials and Methods: Preterm babies who were mechanically ventilated were included in the study. Simple randomization was performed, and the participants were assigned to either the control or intervention group. All neonates received standard care. The intervention group ( n = 37) received azithromycin, while the control group ( n = 37) received saline. The primary outcome was all-cause mortality during hospitalization. Results: No significant differences were observed between the two groups in terms of baseline characteristics, mode of delivery, or duration of mechanical ventilation support. The mortality rates were 47.4% and 43.2% in the azithromycin and control groups, respectively. There was no significant reduction in the mortality rate in the azithromycin group (relative risk [RR] 1.10, 95% confidence interval [CI] 0.67–1.80; p = 0.818). The absolute risk difference was 4.1%. Azithromycin was not associated with mortality even after adjustment for important clinical variables (adjusted RR 0.86, 95% CI 0.43–1.72). Conclusion: Azithromycin administration did not result in a statistically significantly reduce mortality in mechanically ventilated preterm neonates.